| dc.contributor.author | Haine, Valérie | |
| dc.contributor.author | Oneko, Martina | |
| dc.contributor.author | Debois, Muriel.et .al. | |
| dc.date.accessioned | 2025-09-10T08:33:56Z | |
| dc.date.available | 2025-09-10T08:33:56Z | |
| dc.date.issued | 2025-06-01 | |
| dc.identifier.uri | https://repository.maseno.ac.ke/handle/123456789/6346 | |
| dc.description | The Lancet Global Health | en_US |
| dc.description.abstract | RTS,S/AS01E has been successfully administered to over two million children since 2019 through the
Malaria Vaccine Implementation Programme (MVIP). In this Article, we report the safety results of a study evaluating
RTS,S/AS01E safety and effectiveness in real-world settings. | en_US |
| dc.description.sponsorship | GSK | en_US |
| dc.publisher | Elsevier | en_US |
| dc.title | Safety of RTS, S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study | en_US |
| dc.type | Article | en_US |
